The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2010 Jan 13

PMID 20066136

Citations 9

Authors

Omar M Kaisar

David W Johnson

Judith B Prins

Nicole Isbel

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) remains a major cause of premature death in patients with chronic kidney disease (CKD), including renal transplant recipients. Both interplay of traditional cardiovascular and renal specific risk factors have been shown to be associated with an increased risk of cardiovascular death in patients with CKD. Recently, there has been great interest in the role of novel biomarkers, in particular adiponectin and leptin, and its association with CVD in the CKD population. Adiponectin is a multifunctional adipocyte-derived protein with anti-inflammatory, antiatherogenic and insulin sensitizing activity. Recent observational studies have shown adiponectin to be a novel risk marker of CVD in patients with stages 1 to 5 CKD. Leptin is an adipocyte-derived hormone that promotes weight loss by decreasing food intake. Similarly, there are observational studies to support an association between leptin and CVD, including patients with CKD. In the CKD population, leptin may be associated with uremic cachexia and subsequent increased mortality. This review aims to summarize the pathophysiological and potential clinical roles of these cardiovascular biomarkers in patients with CKD.

Citing Articles

Advances in Cardiovascular Biomarker Discovery.

Ghantous C, Kamareddine L, Farhat R, Zouein F, Mondello S, Kobeissy F Biomedicines. 2020; 8(12).

PMID: 33265898 PMC: 7759775. DOI: 10.3390/biomedicines8120552.

Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease.

DMarco L, Puchades M, Gorriz J, Romero-Parra M, Lima-Martinez M, Soto C Int J Mol Sci. 2020; 21(3).

PMID: 32024124 PMC: 7037723. DOI: 10.3390/ijms21030978.

Selected cardiovascular risk factors in early stages of chronic kidney disease.

Jagiela J, Bartnicki P, Rysz J Int Urol Nephrol. 2020; 52(2):303-314.

PMID: 31955363 DOI: 10.1007/s11255-019-02349-1.

Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality.

Valente M, Rocha S, Coimbra S, Catarino C, Rocha-Pereira P, Bronze-da-Rocha E Mediators Inflamm. 2019; 2019:3295725.

PMID: 31316299 PMC: 6604294. DOI: 10.1155/2019/3295725.

A prospective evaluation of obesometric parameters associated with renal stone recurrence.

Bos D, Dason S, Matsumoto E, Pinthus J, Allard C Can Urol Assoc J. 2016; 10(7-8):234-238.

PMID: 27878041 PMC: 5110420. DOI: 10.5489/cuaj.3876.

References

Kern P, Di Gregorio G, Lu T, Rassouli N, Ranganathan G . Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52(7):1779-85. DOI: 10.2337/diabetes.52.7.1779. View

Becker B, Kronenberg F, Kielstein J, Haller H, Morath C, Ritz E . Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16(4):1091-8. DOI: 10.1681/ASN.2004090742. View

Yenicesu M, Yilmaz M, Caglar K, Sonmez A, Eyileten T, Acikel C . Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract. 2005; 99(4):c115-21. DOI: 10.1159/000083929. View

Kon Koh K, Quon M, Han S, Chung W, Ahn J, Seo Y . Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004; 110(24):3687-92. DOI: 10.1161/01.CIR.0000143085.86697.13. View

Villarreal D, Reams G, Freeman R . Effects of renal denervation on the sodium excretory actions of leptin in hypertensive rats. Kidney Int. 2000; 58(3):989-94. DOI: 10.1046/j.1523-1755.2000.00256.x. View

Lord G, Matarese G, Howard J, Baker R, Bloom S, Lechler R . Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998; 394(6696):897-901. DOI: 10.1038/29795. View

Oflaz H, Ozbey N, Mantar F, Genchellac H, Mercanoglu F, Sencer E . Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab. 2003; 16(3):176-81. View

Ejerblad E, Fored C, Lindblad P, Fryzek J, McLaughlin J, Nyren O . Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006; 17(6):1695-702. DOI: 10.1681/ASN.2005060638. View

van den Beld A, Bots M, Janssen J, Pols H, Lamberts S, Grobbee D . Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2002; 157(1):25-31. DOI: 10.1093/aje/kwf160. View

10.

Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y . High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997; 10(10 Pt 1):1171-4. DOI: 10.1016/s0895-7061(97)00310-5. View

11.

Johansen K, Mulligan K, Tai V, Schambelan M . Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol. 1998; 9(6):1080-4. DOI: 10.1681/ASN.V961080. View

12.

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

13.

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View

14.

Wallerstedt S, Eriksson A, Niklason A, Ohlsson C, Hedner T . Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13(4):243-6. DOI: 10.1080/08037050410021405. View

15.

Watson A, Poloyac S, Howard G, Blouin R . Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos. 1999; 27(6):695-700. View

16.

Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P . Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001; 25(6):805-10. DOI: 10.1038/sj.ijo.0801623. View

17.

Banks W . Blood-brain barrier and energy balance. Obesity (Silver Spring). 2006; 14 Suppl 5:234S-237S. DOI: 10.1038/oby.2006.315. View

18.

Yu J, Javorschi S, Hevener A, Kruszynska Y, Norman R, Sinha M . The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002; 51(10):2968-74. DOI: 10.2337/diabetes.51.10.2968. View

19.

Kon Koh K, Quon M, Han S, Ahn J, Jin D, Kim H . Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005; 45(6):1088-93. DOI: 10.1161/01.HYP.0000166722.91714.ba. View

20.

Kaisar M, Isbel N, Johnson D . Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials. 2008; 3(2):79-88. DOI: 10.2174/157488708784223853. View